A5059536209- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
- T-cell and Retrovirus Studies
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Chronic Myeloid Leukemia Treatments
- Cancer-related Molecular Pathways
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Toxin Mechanisms and Immunotoxins
- Monoclonal and Polyclonal Antibodies Research
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Biochemical and Molecular Research
- Retinoids in leukemia and cellular processes
- Genomic variations and chromosomal abnormalities
- Fungal Infections and Studies
- CNS Lymphoma Diagnosis and Treatment
Royal Marsden NHS Foundation Trust
2015-2024
Daresbury Laboratory
2024
Institute of Cancer Research
2010-2023
Royal Marsden Hospital
2013-2022
Royal Ottawa Mental Health Centre
2006-2022
Cancer Research UK
2011-2019
Bladder Cancer Advocacy Network
2014
Integra (United States)
2014
National Health Service
2007-2012
Royal Liverpool and Broadgreen University Hospital NHS Trust
2012
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy adverse cytogenetic abnormalities are associated poor outcome. We evaluated the efficacy ibrutinib, covalent inhibitor Bruton's tyrosine kinase, in at risk for
TP53 mutations have been described in chronic lymphocytic leukemia (CLL) and associated with poor prognosis retrospective studies. We aimed to address the frequency prognostic value of abnormalities patients CLL context a prospective randomized trial.We analyzed 529 samples from LRF CLL4 (Leukaemia Research Foundation Chronic Lymphocytic Leukemia 4) trial (chlorambucil v fludarabine or without cyclophosphamide) at time random assignment for gene. mutation status was correlated response...
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), rare B malignancy with high CD22 expression. The enrolled patients relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 for ≤6 cycles. Blinded independent central review determined disease response minimal residual (MRD)...
We report long-term follow-up from the RESONATE-2 phase 3 study of once-daily Bruton's tyrosine kinase inhibitor ibrutinib, which is only targeted therapy with significant progression-free survival (PFS) and overall (OS) benefit in multiple randomized chronic lymphocytic leukemia (CLL) studies. Patients (≥65 years) previously untreated CLL, without del(17p), were randomly assigned 1:1 to ibrutinib 420 mg until disease progression/unacceptable toxicity (n = 136) or chlorambucil 0.5-0.8 mg/kg...
Summary Hairy cell leukaemia (HCL) was first described 50 years ago. Median survival then 4 years. The purine analogues, introduced in the 1980s, transformed this prognosis. We reviewed data retrospectively from 233 patients, treated with pentostatin ( n = 188) or cladribine 45), to investigate current long‐term outlook. follow‐up 16 There were no significant differences outcome between two agents. Overall, complete response (CR) rate 80% and median relapse‐free After relapse 79)...
To assess the results of treatment with purine analog 2'deoxycoformycin (pentostatin [DCF]) in patients postthymic T-cell malignancies.One hundred forty-five malignancies were given DCF intravenously at 4 mg/m2/wk for first weeks and then every 2 until maximal response; last 30 received weekly injections response.The overall response rate was 32% (complete responses [CRs] plus partial [PRs]), marked variation according to diagnosis. The best occurred Sézary syndrome (62%) T-prolymphocytic...
The majority of disease-specific complications in chronic lymphocytic leukemia (CLL), notably infection and autoimmunity, relate to the underlying alterations immune function. Both cellular humoral immunity are impaired with qualitative quantitative defects B cells, T NK neutrophils monocyte/macrophage lineage. Virtually all patients have reduced immunoglobulin levels, even early stages, this is associated an increased frequency severity infection. Although prophylactic intravenous may be...
Purpose In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly associated with an adverse outcome and resistance to chemotherapy-based treatment. contrast, defects are not the anti-CD52 monoclonal antibody alemtuzumab or methylprednisolone. attempt improve treatment of TP53-defective CLL, a multicenter phase II study was developed evaluate methylprednisolone in combination. Patients Methods Thirty-nine patients TP53-deleted CLL (17 untreated 22 previously treated) received...
The guideline group was selected to be representative of UK based medical experts and patients representatives. Recommendations are on a review the literature using Medline/Pubmed searches under heading, chronic lymphocytic leukaemia, up August 2011, data presented at American Society Haematology in 2011. writing produced draft guideline, which subsequently revised by consensus members Haemato-oncology Task Force British Committee for Standards (BCSH). then reviewed sounding board...
Linked Editorial:Wang and Bagot. Br J Dermatol 2019; 180:443–444.
Abstract Several chronic lymphocytic leukaemia (CLL) susceptibility loci have been reported; however, much of the heritable risk remains unidentified. Here we perform a meta-analysis six genome-wide association studies, imputed using merged reference panel 1,000 Genomes and UK10K data, totalling 6,200 cases 17,598 controls after replication. We identify nine at 1p36.11 (rs34676223, P =5.04 × 10 −13 ), 1q42.13 (rs41271473, =1.06 −10 4q24 (rs71597109, =1.37 4q35.1 (rs57214277, =3.69 −8 6p21.31...
Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of pivotal, multicenter, open-label trial (NCT01829711) moxetumomab in patients with relapsed/refractory (R/R) hairy cell leukemia (HCL).Eligible had received ≥ 2 prior systemic therapies, including purine nucleoside analogs (PNAs), or 1 PNA followed by rituximab BRAF inhibitor. Patients 40 µg/kg intravenously on Days 1, 3, and 5 each 28-day cycle for up to six cycles. Disease...